"The announcement of Third Harmonic Bio's shutdown comes after substantial layoffs and signifies a crucial turning point for the company, emphasizing challenges in continuing its operations ahead."
"Third Harmonic's board unanimously approved a liquidation plan, with stock prices rising in anticipation of a per-share payout, reflecting investor sentiment on the dissolution."
"With a Phase 2 trial in the works for its hives drug, Third Harmonic aims to enhance its asset value even as it moves towards liquidation."
Third Harmonic Bio, a biotech company focused on inflammatory disease research, has decided to shut down and liquidate its assets after laying off half its staff in February. Their board approved a liquidation plan for shareholder vote, and with significant cash reserves, the company's stock rose in anticipation of a payout. While the management emphasizes the potential of their drug for chronic spontaneous urticaria, the shutdown marks a significant setback for investors and employees as they navigate this dissolution process and its implications for future operations.
Read at SFGATE
Unable to calculate read time
Collection
[
|
...
]